HEXIMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.013 AUD | +8.33% |
|
+8.33% | -27.78% |
| Mar. 22 | Hexima Secures R&D Tax Rebate for Fiscal Year 2023 | MT |
| Mar. 19 | Hexima Changes Address | MT |
| Sales 2022 | 5.81M 3.73M | Sales 2023 | 1.48M 953K | Capitalization | 3.51M 2.25M |
|---|---|---|---|---|---|
| Net income 2022 | -10M -6.42M | Net income 2023 | -1M -642K | EV / Sales 2022 | 0.18 x |
| Net cash position 2022 | 3.96M 2.54M | Net cash position 2023 | 2.19M 1.4M | EV / Sales 2023 | 0.89 x |
| P/E ratio 2022 |
-0.46
x | P/E ratio 2023 |
-1.83
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 36.17% |
More Fundamentals
* Assessed data
More news
| 1 day | +8.33% | ||
| 1 week | +8.33% | ||
| Current month | +8.33% | ||
| 3 months | -27.78% | ||
| 6 months | -43.48% | ||
| Current year | -27.78% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.010.02
1 year
0.010.02
3 years
0.010.50
5 years
0.010.50
10 years
0.010.50
| Managers | Title | Age | Since |
|---|---|---|---|
Geoffrey Kempler
CEO | Chief Executive Officer | 69 | 23-09-04 |
Leanne Ralph
SEC | Corporate Secretary | - | 21-10-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Geoffrey Kempler
CEO | Chief Executive Officer | 69 | 23-09-04 |
Phillip Hains
BRD | Director/Board Member | 64 | 23-09-17 |
Zhen Nan Yap
BRD | Director/Board Member | - | 18-07-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 0.013 | +8.33% | 400,251 |
| 24-04-16 | 0.012 | +9.09% | 30,000 |
| 24-04-15 | 0.011 | 0.00% | 625,000 |
| 24-04-12 | 0.011 | -8.33% | 1,006,276 |
| 24-04-11 | 0.012 | -14.29% | 956,058 |
Delayed Quote Australian S.E., April 17, 2024 at 02:10 am EDT
More quotes
Hexima Limited is an Australia-based clinical-stage, anti-infectives focused biotechnology company. The Company is engaged in the research and development of plant defensin peptides for applications in human therapeutics. Its lead drug candidate is the plant defensin, pezadeftide, developed for the treatment of fungal nail infections. The Company is conducting phase II clinical trial testing pezadeftide as a treatment for onychomycosis. Its Antifungal Plant Defensin Technology platform is engaged in identifying several plant peptides with potent antifungal activity against a broad range of human fungal pathogens. It is also investigating the application of its plant defensin technology to other human fungal diseases.
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.78% | 1.4M | |
| -1.82% | 41.35B | |
| +41.53% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- HXL Stock
